200,000+ products from a single source!
sales@angenechem.com
Home > Boronic Acids > 149682-77-9
149682-77-9 | VAL-BORO-PRO
CAS No: 149682-77-9 Catalog No: AG00AOWA MDL No:MFCD09833674
Product Description
Catalog Number:
AG00AOWA
Chemical Name:
VAL-BORO-PRO
CAS Number:
149682-77-9
Molecular Formula:
C9H19BN2O3
Molecular Weight:
214.0698
MDL Number:
MFCD09833674
IUPAC Name:
[(2R)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid
InChI:
InChI=1S/C9H19BN2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8,14-15H,3-5,11H2,1-2H3/t7-,8-/m0/s1
InChI Key:
FKCMADOPPWWGNZ-YUMQZZPRSA-N
SMILES:
CC([C@@H](C(=O)N1CCC[C@H]1B(O)O)N)C
UNII:
KZ1O2SH88Z
Properties
Complexity:
235
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
2
Defined Bond Stereocenter Count:
0
Exact Mass:
214.149g/mol
Formal Charge:
0
Heavy Atom Count:
15
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
214.072g/mol
Monoisotopic Mass:
214.149g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
86.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Inhibition of Dpp8/9 Activates the Nlrp1b Inflammasome. | Cell chemical biology 20180315 |
| Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. | European journal of pharmacology 20170815 |
| DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. | Nature chemical biology 20170101 |
| Targeting of cancer‑associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. | Molecular medicine reports 20160301 |
| A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. | Nature chemical biology 20140801 |
| Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. | Journal of medicinal chemistry 20130509 |
| Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. | Bioorganic & medicinal chemistry letters 20120515 |
| Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. | Clinical & experimental metastasis 20110801 |
| Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases. | Journal of medicinal chemistry 20110414 |
| Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. | The Journal of general virology 20110101 |
| Pediatric phase I trial design using maximum target inhibition as the primary endpoint. | Journal of the National Cancer Institute 20100616 |
| From melanocyte to metastatic malignant melanoma. | Dermatology research and practice 20100101 |
| Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20090801 |
| Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. | British journal of haematology 20090601 |
| Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. | BMC cancer 20090101 |
| Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. | Journal of medicinal chemistry 20081009 |
| HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat. | Biochemical and biophysical research communications 20080523 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. | Cancer biology & therapy 20071101 |
| Talabostat. | Expert opinion on investigational drugs 20070901 |
| Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. | Journal of medicinal chemistry 20070517 |
| Dipeptidyl peptidase 8/9-like activity in human leukocytes. | Journal of leukocyte biology 20070501 |
| Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. | Bioorganic & medicinal chemistry letters 20070115 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061201 |
| Molecule of the month. Talabostat. | Drug news & perspectives 20060601 |
| Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors. | Bioorganic & medicinal chemistry letters 20041115 |
| Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases. | Journal of medicinal chemistry 20031106 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.